{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T10:14:40Z","timestamp":1795256080316,"version":"4.10.3"},"reference-count":111,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2023,12,24]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities (cirrhosis, liver failure and hepatocellular carcinoma) and extrahepatic complications, such as cardiovascular disease (CVD), type 2 diabetes mellitus, chronic kidney disease, and certain types of extrahepatic cancers. In 2023, three large multinational liver associations proposed that metabolic dysfunction-associated steatotic liver disease (MASLD) should replace the term NAFLD; the name chosen to replace non-alcoholic steatohepatitis was metabolic dysfunction-associated steatohepatitis (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between NAFLD and MASLD definitions\u2014that is, ~99% of individuals with NAFLD meet MASLD criteria. In this narrative review, we provide an overview of the literature on (a) the recent epidemiological data on MASLD and the risk of developing CVD and malignant complications, (b) the underlying mechanisms by which MASLD (and factors strongly linked with MASLD) may increase the risk of these extrahepatic complications and (c) the diagnosis and assessment of CVD risk and potential treatments to reduce CVD risk in people with MASLD or MASH.<\/jats:p>","DOI":"10.1136\/gutjnl-2023-330595","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T13:26:32Z","timestamp":1705411592000},"page":"691-702","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":806,"title":["MASLD: a systemic metabolic disorder with cardiovascular and malignant complications"],"prefix":"10.1136","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"first","affiliation":[{"name":"Metabolic Diseases Research Unit, IRCCS Sacro Cuore Don Calabria Hospital and Department of Medicine University of Verona, Negrar di Valpolicella (VR), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-7753","authenticated-orcid":false,"given":"Christopher D","family":"Byrne","sequence":"additional","affiliation":[{"name":"Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-2579","authenticated-orcid":false,"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2025121222320533000_73.4.691.1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01701-3"},{"key":"2025121222320533000_73.4.691.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"2025121222320533000_73.4.691.4","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a Multisystem disease requiring a Multidisciplinary and Holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2025121222320533000_73.4.691.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y"},{"key":"2025121222320533000_73.4.691.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313884"},{"key":"2025121222320533000_73.4.691.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"2025121222320533000_73.4.691.8","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A Multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.9","doi-asserted-by":"crossref","unstructured":"Hagstr\u00f6m H , Vessby J , Ekstedt M , et al . 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. Journal of Hepatology September 2023. doi:10.1016\/j.jhep.2023.08.026","DOI":"10.1016\/j.jhep.2023.08.026"},{"key":"2025121222320533000_73.4.691.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"2025121222320533000_73.4.691.11","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004"},{"key":"2025121222320533000_73.4.691.12","doi-asserted-by":"crossref","unstructured":"Duell PB , Welty FK , Miller M , et al . Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart Association. ATVB 2022;42. doi:10.1161\/ATV.0000000000000153","DOI":"10.1161\/ATV.0000000000000153"},{"key":"2025121222320533000_73.4.691.13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international Multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"key":"2025121222320533000_73.4.691.14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325724"},{"key":"2025121222320533000_73.4.691.15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2025121222320533000_73.4.691.16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331003"},{"key":"2025121222320533000_73.4.691.17","doi-asserted-by":"crossref","unstructured":"Chen J , Sun Y , Fu T , et al . Risk of incident cardiovascular disease among patients with gastrointestinal disorder: a prospective cohort study of 330,751 individuals. Eur Heart J Qual Care Clin Outcomes 2023:qcad059. doi:10.1093\/ehjqcco\/qcad059","DOI":"10.1093\/ehjqcco\/qcad059"},{"key":"2025121222320533000_73.4.691.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.046"},{"key":"2025121222320533000_73.4.691.19","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.cgh.2023.01.006","article-title":"Nonalcoholic fatty liver disease is independently associated with higher all-cause and cause-specific mortality","volume":"21","author":"de Avila","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121222320533000_73.4.691.20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with Nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025121222320533000_73.4.691.21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-022-10319-6","article-title":"Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis","volume":"16","author":"Yong","year":"2022","journal-title":"Hepatol Int"},{"key":"2025121222320533000_73.4.691.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.04.162","article-title":"Aortic valve sclerosis as a marker of Atherosclerosis: novel insights from hepatic steatosis","volume":"217","author":"Di Minno","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025121222320533000_73.4.691.23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"key":"2025121222320533000_73.4.691.24","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/liv.14461","article-title":"Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation","volume":"40","author":"Cai","year":"2020","journal-title":"Liver Int"},{"key":"2025121222320533000_73.4.691.25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327672"},{"key":"2025121222320533000_73.4.691.26","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients","volume":"112","author":"Roderburg","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2025121222320533000_73.4.691.27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025121222320533000_73.4.691.28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2021.08.028","article-title":"Rational HCC screening approaches for patients with NAFLD","volume":"76","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"173","author":"Thomas","year":"2022","journal-title":"European Journal of Cancer"},{"key":"2025121222320533000_73.4.691.30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324191"},{"key":"2025121222320533000_73.4.691.31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328887"},{"key":"2025121222320533000_73.4.691.32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322786"},{"key":"2025121222320533000_73.4.691.33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31845"},{"key":"2025121222320533000_73.4.691.34","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.22.01740","article-title":"Increased risk of young-onset digestive tract cancers among young adults age 20-39 years with Nonalcoholic fatty liver disease: A nationwide cohort study","volume":"41","author":"Park","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025121222320533000_73.4.691.35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.21037\/hbsn-21-546","article-title":"Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China","volume":"12","author":"Yuan","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025121222320533000_73.4.691.36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/liv.15195","article-title":"Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study","volume":"42","author":"Bj\u00f6rkstr\u00f6m","year":"2022","journal-title":"Liver Int"},{"key":"2025121222320533000_73.4.691.37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"44","author":"Souza","year":"2024","journal-title":"Liver Int"},{"key":"2025121222320533000_73.4.691.38","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, Microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"2025121222320533000_73.4.691.39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001"},{"key":"2025121222320533000_73.4.691.40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60777"},{"key":"2025121222320533000_73.4.691.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022"},{"key":"2025121222320533000_73.4.691.42","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/HEP.0000000000000386","article-title":"Therapeutic modulation of the liver immune Microenvironment","volume":"78","author":"Tilg","year":"2023","journal-title":"Hepatology"},{"key":"2025121222320533000_73.4.691.43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa099"},{"key":"2025121222320533000_73.4.691.44","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205"},{"key":"2025121222320533000_73.4.691.45","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jhep.2023.08.023","article-title":"Hepatic steatosis aggravates Atherosclerosis via small extracellular Vesicle-mediated inhibition of cellular cholesterol efflux","volume":"79","author":"Chen","year":"2023","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00271-5"},{"key":"2025121222320533000_73.4.691.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"2025121222320533000_73.4.691.48","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.31250","article-title":"The role of metabolic Lipases in the pathogenesis and management of liver disease","volume":"72","author":"Tardelli","year":"2020","journal-title":"Hepatology"},{"key":"2025121222320533000_73.4.691.49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8798","article-title":"Targeting acid Ceramidase inhibits YAP\/TAZ signaling to reduce fibrosis in mice","volume":"12","author":"Alsamman","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025121222320533000_73.4.691.50","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.054"},{"key":"2025121222320533000_73.4.691.51","doi-asserted-by":"publisher","DOI":"10.1038\/nm1166"},{"key":"2025121222320533000_73.4.691.52","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3084"},{"key":"2025121222320533000_73.4.691.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.034"},{"key":"2025121222320533000_73.4.691.54","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s42255-021-00470-z","article-title":"Metabolic messengers: tumour necrosis factor","volume":"3","author":"Sethi","year":"2021","journal-title":"Nat Metab"},{"key":"2025121222320533000_73.4.691.55","doi-asserted-by":"publisher","DOI":"10.1038\/nature21363"},{"key":"2025121222320533000_73.4.691.56","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-020-01207-9","article-title":"Independent and joint correlation of Pnpla3 I148m and Tm6Sf2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease","volume":"19","author":"Wu","year":"2020","journal-title":"Lipids Health Dis"},{"key":"2025121222320533000_73.4.691.57","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-021-02020-z","article-title":"Pnpla3 genotype and Fibrosis-4 index predict cardiovascular diseases of Japanese patients with Histopathologically-confirmed NAFLD","volume":"21","author":"Akuta","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2025121222320533000_73.4.691.58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074089","article-title":"Pnpla3 GG genotype and carotid Atherosclerosis in patients with non-alcoholic fatty liver disease","volume":"8","author":"Petta","year":"2013","journal-title":"PLoS ONE"},{"key":"2025121222320533000_73.4.691.59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","article-title":"Current concepts, opportunities, and challenges of gut Microbiome-based personalized medicine in Nonalcoholic fatty liver disease","volume":"33","author":"Sharpton","year":"2021","journal-title":"Cell Metabolism"},{"key":"2025121222320533000_73.4.691.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.04.001"},{"key":"2025121222320533000_73.4.691.61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk0855","article-title":"Risk assessment with gut Microbiome and metabolite markers in NAFLD development","volume":"14","author":"Leung","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025121222320533000_73.4.691.62","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322753"},{"key":"2025121222320533000_73.4.691.63","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic fatty liver disease: Modulating gut Microbiota to improve severity","volume":"158","author":"Aron-Wisnewsky","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121222320533000_73.4.691.64","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1123547","article-title":"Faecalibacterium Prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet","volume":"14","author":"Shin","year":"2023","journal-title":"Front Microbiol"},{"key":"2025121222320533000_73.4.691.65","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.07.005"},{"key":"2025121222320533000_73.4.691.66","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of Lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"key":"2025121222320533000_73.4.691.67","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318811"},{"key":"2025121222320533000_73.4.691.68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut Microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025121222320533000_73.4.691.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.07.015"},{"key":"2025121222320533000_73.4.691.70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.036"},{"key":"2025121222320533000_73.4.691.71","doi-asserted-by":"publisher","DOI":"10.1126\/science.1214914"},{"key":"2025121222320533000_73.4.691.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.09.025"},{"key":"2025121222320533000_73.4.691.73","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.01.034"},{"key":"2025121222320533000_73.4.691.74","doi-asserted-by":"publisher","DOI":"10.1038\/nature11225"},{"key":"2025121222320533000_73.4.691.75","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316242"},{"key":"2025121222320533000_73.4.691.76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00215-5"},{"key":"2025121222320533000_73.4.691.77","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cmet.2023.06.011","article-title":"Inflammation and cholesterol at the crossroads of vascular risk","volume":"35","author":"Verma","year":"2023","journal-title":"Cell Metab"},{"key":"2025121222320533000_73.4.691.78","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1012887","article-title":"Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD","volume":"13","author":"Huang","year":"2022","journal-title":"Front Physiol"},{"key":"2025121222320533000_73.4.691.79","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2217\/bmm.15.71","article-title":"Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic Steatohepatitis","volume":"9","author":"Hendrikx","year":"2015","journal-title":"Biomark Med"},{"key":"2025121222320533000_73.4.691.80","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and Antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"Journal of Hepatology"},{"key":"2025121222320533000_73.4.691.81","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324915"},{"key":"2025121222320533000_73.4.691.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.052"},{"key":"2025121222320533000_73.4.691.83","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2010.183"},{"key":"2025121222320533000_73.4.691.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.031"},{"key":"2025121222320533000_73.4.691.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.06.016"},{"key":"2025121222320533000_73.4.691.86","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh0831","article-title":"Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC","volume":"9","author":"Boslem","year":"2023","journal-title":"Sci Adv"},{"key":"2025121222320533000_73.4.691.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.05.001"},{"key":"2025121222320533000_73.4.691.88","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.11.019"},{"key":"2025121222320533000_73.4.691.89","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2023.02.033","article-title":"Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation","volume":"79","author":"Yahoo","year":"2023","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.90","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03233-8"},{"key":"2025121222320533000_73.4.691.91","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0"},{"key":"2025121222320533000_73.4.691.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.012"},{"key":"2025121222320533000_73.4.691.93","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","article-title":"Familial Coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide Multigenerational cohort study","volume":"79","author":"Ebrahimi","year":"2023","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.94","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328887"},{"key":"2025121222320533000_73.4.691.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002449"},{"key":"2025121222320533000_73.4.691.96","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/SLA.0000000000006003","article-title":"Decreased risk of Esophageal adenocarcinoma after gastric bypass surgery in a cohort study from 3 Nordic countries","volume":"278","author":"Hardvik \u00c5kerstr\u00f6m","year":"2023","journal-title":"Ann Surg"},{"key":"2025121222320533000_73.4.691.97","doi-asserted-by":"publisher","DOI":"10.1038\/nri1937"},{"key":"2025121222320533000_73.4.691.98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02377.x"},{"key":"2025121222320533000_73.4.691.99","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.13.1523"},{"key":"2025121222320533000_73.4.691.100","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e32834c9b55"},{"key":"2025121222320533000_73.4.691.101","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159293"},{"key":"2025121222320533000_73.4.691.102","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.037010"},{"key":"2025121222320533000_73.4.691.103","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678"},{"key":"2025121222320533000_73.4.691.104","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"2025121222320533000_73.4.691.105","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678"},{"key":"2025121222320533000_73.4.691.106","unstructured":"CVD risk assessment and management. 2023. Available: https:\/\/cksniceorguk\/topics\/cvd-risk-assessment-management\/"},{"key":"2025121222320533000_73.4.691.107","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"2025121222320533000_73.4.691.108","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","article-title":"Score2-diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"key":"2025121222320533000_73.4.691.109","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"Group SW, collaboration Ecr. Score2 risk prediction Algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"2025121222320533000_73.4.691.110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and Epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"2025121222320533000_73.4.691.111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the direct open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2023-330595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:32:17Z","timestamp":1765607537000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2023-330595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/gutjnl-2023-330595"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2023-330595","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}